TABLE 3

Univariate analysis of clinical features associated with inpatient mortality

ParameteraValue for the groupP value
Nonsurvivors (n = 27)Survivors (n = 60)
Median (IQR) age (yr)65.0 (56.0–80.0)59.0 (56.0–80.0)0.132
Median SOFA score (IQR)8 (6–9)5 (3–7)0.001
Median Charlson score (IQR)6 (4–7)5 (2–7)0.115
No. (%) of female patients8 (29.6)26 (43.3)0.226
Clinical factors (no. of patients [%])
    Diabetes10 (37.0)22 (36.7)0.974
    History of CVA7 (25.9)16 (26.7)0.942
    Any respiratory pathology14 (51.9)26 (43.3)0.635
    HIV/AIDS2 (7.4)3 (5.0)0.655
    Liver disease3 (11.1)6 (10.0)0.875
    Intravenous drug use6 (22.2)13 (21.7)0.952
    Acute kidney injury8 (29.6)31 (51.7)0.152
    Hemodialysis1 (3.7)6 (10.0)0.318
No. (%) of patients with prior hospitalization11 (40.7)36 (60.0)0.095
Antibiotic use in the last 30 days (no. of patients [%])2 (7.4)11 (18.3)0.396
Previous vancomycin treatment (30 days)2 (7.4)10 (16.7)0.247
Vancomycin therapy (no. of patients [%])
    Vancomycin trough of <15 mg/liter11 (45.8)31 (57.4)0.344
    No change in antibiotic therapy14 (51.9)39 (65.0)0.245
ID consult (no. of patients [%])11 (40.7)40 (66.7)0.023
Concurrent bacteremia (no. of patients [%])25 (92.6)54 (90.0)0.207
Median (IQR) duration of bacteremia (days)3 (1–6)2 (1–5)0.717
Presence of concurrent sites of infection (no. of patients [%])
    Skin/soft tissue4 (14.8)11 (18.3)0.688
    Deep abscess0 (0.0)1 (1.7)0.500
    Infective endocarditis2 (7.4)2 (3.3)0.401
    Bone/joint1 (3.7)2 (3.3)0.930
    Unknown4 (14.8)8 (13.3)0.853
ICU admission (no. of patients [%])23 (85.2)41 (63.8)0.099
No. (%) of patients receiving mechanical ventilation (any)21 (77.8)34 (56.7)0.059
Presence of other respiratory pathogens (no. of patients [%])
    Acinetobacter spp.4 (14.8)7 (11.7)0.683
    Pseudomonas spp.2 (7.4)8 (13.3)0.423
    Klebsiella spp.0 (0.0)8 (13.3)0.046
    Streptococcal spp.1 (3.7)8 (8.3)0.430
Presence of MRSA isolate type (no. of patients [%])
    hVISA phenotype13 (48.1)14 (23.3)0.049
    VAN MIC of 2 mg/liter (BMD)4 (15.4)5 (8.8)0.501
    SCCmec type II13 (48.1)30 (50.0)0.873
    PVL positive13 (48.1)10 (16.7)0.002
    USA3008 (29.6)14 (23.3)0.532
    agr type II14 (51.9)27 (45.0)0.554
    agr dysfunction8 (29.6)23 (38.3)0.433
  • a IQR, interquartile range; SOFA, sequential organ failure assessment; CVA, cerebrovascular accident; HIV, human immunodeficiency virus; MRSA, methicillin-resistant S. aureus; hVISA, heterogeneous vancomycin-intermediate S. aureus.